FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FRK | Fyn-related Src family tyrosine kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
FTL | Ferritin, light polypeptide | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GAA | Glucosidase, alpha; acid | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRB2 | Gamma-aminobutyric acid (GABA) A receptor, beta 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRD | Gamma-aminobutyric acid (GABA) A receptor, delta | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
GART | Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GGPS1 | Geranylgeranyl diphosphate synthase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GLP2R | Glucagon-like peptide 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
GRIA1 | Glutamate receptor, ionotropic, AMPA 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
GRIN2A | Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enriched |
GSR | Glutathione reductase | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GSS | Glutathione synthetase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HBA1 | Hemoglobin, alpha 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
HBA2 | Hemoglobin, alpha 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
HDAC1 | Histone deacetylase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC2 | Histone deacetylase 2 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC3 | Histone deacetylase 3 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
HDAC6 | Histone deacetylase 6 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
HMMR | Hyaluronan-mediated motility receptor (RHAMM) | CD markers FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
HPD | 4-hydroxyphenylpyruvate dioxygenase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HRH1 | Histamine receptor H1 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IMPDH1 | IMP (inosine 5'-monophosphate) dehydrogenase 1 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
IMPDH2 | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAV | Integrin, alpha V | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
JUN | Jun proto-oncogene | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |